OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
13 October 2021OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure Quebec, Quebec, October 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire,…
OpSens Presents at Lytham Partners Fall Conference
5 October 2021OpSens to Present at the Lytham Partners Fall 2021 Investor Conference – Tuesday, October 5, 2021, 9:30 AM
29 September 2021OPSENS TO PRESENT AT THE LYTHAM PARTNERS FALL 2021 INVESTOR CONFERENCE Presentation at 9:30 AM, Tuesday October 5, 2021 Quebec, Quebec, September 29, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at…
OpSens Receives Approval from Health Canada to Initiate First In-Man Study For its New Guidewire For the TAVR Procedure
20 September 2021OPSENS RECEIVES APPROVAL FROM HEALTH CANADA TO INITIATE FIRST IN-MAN STUDY FOR ITS NEW GUIDEWIRE FOR THE TAVR PROCEDURE SAVVYWIRE, the first guidewire that aims to improve procedural efficiency and clinical outcomes for patients undergoing minimally invasive, Trans Aortic Valve Replacement (TAVR) Quebec, Quebec, September 20, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF)…
OpSens Appoints Lori Chmura to its Board of Directors
8 September 2021OpSens Appoints Lori Chmura to its Board of Directors Quebec City, Quebec, September 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today announced the appointment of Lori Chmura to its board of Directors, effective September 8….
Conference Call Q3
13 July 2021OpSens Announces Third Quarter Fiscal 2021 Record Financial Results
13 July 2021OpSens Announces Third Quarter Fiscal 2021 Record Financial Results Conference call on the results to be held today at 11 a.m. Quebec City, Quebec, July 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today reported its…
OpSens to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesday, July 13
7 July 2021OpSens to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesday, July 13, 2021 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, July 7, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical…
OpSens Solutions Receives Funding Support to Jointly Develop an Optical-Based Fuel Monitoring System for Aerospace Applications, Including Civil Aircrafts
16 June 2021OpSens Solutions Receives Funding Support to Jointly Develop an Optical-Based Fuel Monitoring System for Aerospace Applications, Including Civil Aircrafts Quebec City, Quebec, June 16, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today announced that OpSens Solutions Inc. (“OpSens Solutions”), its wholly-owned subsidiary, is receiving advisory services and up to $500,000 in funding support…
OpSsens Will Participate and Present at Two Investment Conferences Lytham Partners and Raymond James
9 June 2021OPSENS WILL PARTICIPATE AND PRESENT AT TWO INVESTMENT CONFERENCES Lytham Partners and Raymond James Quebec City, Quebec, June 9, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that it will present at…